AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33942396 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 antibodies
Number of subjects: 1
Study 32802319 — intervention group
Group type: EXPERIMENTAL
Intervention: TFS rehabilitation training (30-minute sessions, three times a week for five weeks)
Number of subjects: 30
Study 32802319 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study 34001373 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A)
Number of subjects: 4
Study 34001373 — intervention group
Group type: COMPARATOR
Intervention: Standard relaxation and education protocol
Number of subjects: 4
Study 32367400 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D/D, 5‐HTTLPR I/I haplotype (n=46)
Number of subjects: 507
Study 32367400 — intervention group
Group type: COMPARATOR
Intervention: Non-risk haplotypes (n=461)
Number of subjects: 507
Study 32367400 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE D/D, 5‐HTTLPR I/I haplotype
Number of subjects: 507
Study 32367400 — intervention group
Group type: COMPARATOR
Intervention: Non-risk haplotypes
Number of subjects: 507
Study 35634479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (Group L)
Number of subjects: 72
Study 35634479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalised lidocaine (Group AL)
Number of subjects: 72
Study 32568873 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor aerosol pollution from local cafeterias without ventilation
Number of subjects: 11
Study 32568873 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's activity during lesson breaks
Number of subjects: 11
Study 32568873 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft furniture and carpets in classrooms and corridors
Number of subjects: 11
Study 32568873 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor aerosol pollution in city center schools
Number of subjects: 11
Study 32568873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sources like construction work during classes
Number of subjects: 11
Study 32568873 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of petrol-powered lawn trimmers
Number of subjects: 11
Study 33196927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention including psychoeducation on PND, coping skills, healthy mother/child interaction, and infant stimulation in addition to routine treatment.
Number of subjects: 567
Study 33196927 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving treatment as usual.
Number of subjects: 567
Study 33196927 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 567
Study 32783498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 0
Study 34041633 — intervention group
Group type: COMPARATOR
Intervention: HF-rTMS targeting DLPFC
Number of subjects: 11
Study 34041633 — intervention group
Group type: COMPARATOR
Intervention: HF-rTMS targeting motor cortex
Number of subjects: 11
Study 34041633 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 34041633 — intervention group
Group type: COMPARATOR
Intervention: HF-rTMS (DLPFC and motor cortex)
Number of subjects: 11
Study 35701334 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT), transdermal gel (Tostran, 2%), maximum daily dose of 40 mg for 12 months
Number of subjects: 69
Study 35701334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 35701334 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 69
Study 33092711 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip implantation
Number of subjects: 5184
Study 32052372 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Modeling + Video Feedback (VM+VF)
Number of subjects: 25
Study 32052372 — intervention group
Group type: COMPARATOR
Intervention: Video Modeling alone (VM)
Number of subjects: 25
Study 35511060 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Number of subjects: 0
Study 34570527 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personalized feedback intervention (PFI)
Number of subjects: 164
Study 34570527 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 164
Study 34729060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg for 12 weeks)
Number of subjects: 60
Study 34729060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33963688 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model using logistic regression
Number of subjects: 491
Study 33963688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure imaging-based model
Number of subjects: 491
Study 33963688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (deep learning with clinical factors)
Number of subjects: 491
Study 33963688 — intervention group
Group type: COMPARATOR
Intervention: Deep learning models (with and without clinical factors)
Number of subjects: 491
Study 35074810 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 restrictions
Number of subjects: 104
Study 33845710 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 10
Study 33845710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34132170 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 488
Study 34132170 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 488
Study 33308039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 11
Study 36372869 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C level at 6 months after randomization set at a threshold of 70 mg/dl
Number of subjects: 11105
Study 36372869 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C level below 70 mg/dl
Number of subjects: 11105
Study 35367910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab
Number of subjects: 605
Study 35367910 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 605
Study 33568662 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime napping
Number of subjects: 452633
Study 32617061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid therapy
Number of subjects: 0
Study 32617061 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral macrolide therapy
Number of subjects: 0
Study 32617061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (oral steroid + macrolide)
Number of subjects: 0
Study 32617061 — intervention group
Group type: COMPARATOR
Intervention: Control (Oral steroid group)
Number of subjects: 0
Study 32617061 — intervention group
Group type: COMPARATOR
Intervention: Control (Macrolide group)
Number of subjects: 0
Study 35249859 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (30 exercise sessions within four months)
Number of subjects: 800
Study 35249859 — intervention group
Group type: COMPARATOR
Intervention: Control group (completed measures only)
Number of subjects: 800
Study 32565092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care program (ongoing rehabilitation at specialized care center and home)
Number of subjects: 84
Study 32565092 — intervention group
Group type: COMPARATOR
Intervention: Routine follow‐up visits by primary healthcare physicians (control)
Number of subjects: 84
Study 32487120 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness Route (positive psychology intervention)
Number of subjects: 108
Study 32487120 — intervention group
Group type: COMPARATOR
Intervention: Control condition (traditional problem-based approach)
Number of subjects: 108
Study 32487120 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness Route
Number of subjects: 108
Study 36047035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training & exercise (CT&E)
Number of subjects: 47
Study 36047035 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 47
Study 33908691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exenatide-dapagliflozin
Number of subjects: 66
Study 33908691 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 66
Study 33908691 — intervention group
Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 66
Study 33908691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32195729 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 8
Study 32195729 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional treatment)
Number of subjects: 8
Study 35749371 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal diet and lifestyle intervention
Number of subjects: 645
Study 35749371 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal early pregnancy BMI
Number of subjects: 645
Study 33975465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (fluoropyrimidine and platinum-based agent)
Number of subjects: 1542
Study 33975465 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (fluoropyrimidine and platinum-based agent)
Number of subjects: 1542
Study 33392137 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate change affected scenario (CCA)
Number of subjects: 0
Study 33392137 — intervention group
Group type: COMPARATOR
Intervention: Climate change unaffected scenario (CCU)
Number of subjects: 0
Study 35777110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high protein (MHP) diet
Number of subjects: 190
Study 35777110 — intervention group
Group type: COMPARATOR
Intervention: Low fat (LF) diet
Number of subjects: 190
Study 35777110 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including genetic information
Number of subjects: 190
Study 34463929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (target serum level 3 mg/dl)
Number of subjects: 72
Study 34463929 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo, target serum level 1.9 mg/dl)
Number of subjects: 72
Study 34463929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 72
Study 34463929 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 72
Study 34463929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate and normal saline (placebo)
Number of subjects: 72
Study 36181292 — intervention group
Group type: EXPERIMENTAL
Intervention: 308nm excimer laser
Number of subjects: 21
Study 33108981 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 161
Study 33245004 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 350
Study 33245004 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 350
Study 36277954 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera Lam. leaf supplementation (MOG)
Number of subjects: 200
Study 36277954 — intervention group
Group type: COMPARATOR
Intervention: Control group (COG)
Number of subjects: 200
Study 33003575 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Band Exercise (EBE) for 60 min, three times a week for 12 weeks
Number of subjects: 27
Study 33003575 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Band Exercise (EBE)
Number of subjects: 27
Study 33003575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 34861772 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid Lobectomy (TL)
Number of subjects: 918
Study 34861772 — intervention group
Group type: COMPARATOR
Intervention: Total Thyroidectomy (TT)
Number of subjects: 918
Study 34929497 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized intraoperative infection control program
Number of subjects: 801
Study 32767582 — intervention group
Group type: EXPERIMENTAL
Intervention: LF GA
Number of subjects: 15
Study 32767582 — intervention group
Group type: COMPARATOR
Intervention: HF GA
Number of subjects: 15
Study 32767582 — intervention group
Group type: COMPARATOR
Intervention: LF St
Number of subjects: 15
Study 32209071 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-friendly sexual and reproductive health services
Number of subjects: 54
Study 32209071 — intervention group
Group type: EXPERIMENTAL
Intervention: Input quality (availability of trained providers, drugs, and supplies)
Number of subjects: 54
Study 32209071 — intervention group
Group type: EXPERIMENTAL
Intervention: Process component (client-provider interaction and privacy/confidentiality)
Number of subjects: 54
Study 32209071 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health insurance and age-driven comprehensive youth-friendly service delivery approach
Number of subjects: 54
Study 35247831 — intervention group
Group type: EXPERIMENTAL
Intervention: Workstation adjustments (EG)
Number of subjects: 61
Study 35247831 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study 34649217 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day ALA
Number of subjects: 210
Study 34649217 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day ALA
Number of subjects: 210
Study 34649217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 34972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal tumors
Number of subjects: 340
Study 34972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal tumors
Number of subjects: 340
Study 34972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal tumors
Number of subjects: 340
Study 34972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal tumors (metastatic disease)
Number of subjects: 340
Study 34972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal tumors (metastatic disease)
Number of subjects: 340
Study 34972663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal tumors (metastatic disease)
Number of subjects: 340
Study 34639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation for diabetes mellitus
Number of subjects: 161
Study 34639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Regula Mais Brasil Collaborative project
Number of subjects: 161
Study 34639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Brasil Redes project
Number of subjects: 161
Study 34639518 — intervention group
Group type: EXPERIMENTAL
Intervention: TELEconsulta Diabetes (randomized clinical trial)
Number of subjects: 161
Study 35718935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-pure soft water (UPSW)
Number of subjects: 43
Study 35718935 — intervention group
Group type: COMPARATOR
Intervention: Tap water (TW)
Number of subjects: 43
Study 34473896 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh inlay
Number of subjects: 2632
Study 34473896 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh kit
Number of subjects: 2632
Study 34473896 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological xenograft
Number of subjects: 2632
Study 34473896 — intervention group
Group type: EXPERIMENTAL
Intervention: Native tissue
Number of subjects: 2632
Study 34473896 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2632
Study 36414304 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-poor platelet-rich plasma (PRP) injection after joint aspiration
Number of subjects: 80
Study 36414304 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group receiving only joint aspiration
Number of subjects: 80
Study 35473371 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 28
Study 35473371 — intervention group
Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 28
Study 34559359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol initial infusion for 30 min followed by continuous maintenance infusion for 4 hours
Number of subjects: 16
Study 34559359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol bolus dose followed by continuous maintenance infusion for 12 hours
Number of subjects: 16
Study 34559359 — intervention group
Group type: COMPARATOR
Intervention: Ciprofol and propofol pharmacokinetic parameters
Number of subjects: 16
Study 34559359 — intervention group
Group type: COMPARATOR
Intervention: Ciprofol and propofol pharmacodynamic parameters
Number of subjects: 16
Study 35066398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame training
Number of subjects: 84
Study 35066398 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training
Number of subjects: 84
Study 35066398 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 33622392 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet
Number of subjects: 26
Study 33622392 — intervention group
Group type: COMPARATOR
Intervention: Usual diet supplemented with low-fat healthy-eating guidelines
Number of subjects: 26
Study 32186108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-ear acupuncture
Number of subjects: 152
Study 32186108 — intervention group
Group type: COMPARATOR
Intervention: Standard acupuncture
Number of subjects: 152
Study 32186108 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study 36644351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 36644351 — intervention group
Group type: EXPERIMENTAL
Intervention: SCO-792 500 mg once daily (SCO-792 QD)
Number of subjects: 72
Study 36644351 — intervention group
Group type: EXPERIMENTAL
Intervention: SCO-792 500 mg 3 times daily (SCO-792 TID)
Number of subjects: 72
Study 34345921 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach intervention
Number of subjects: 225
Study 34345921 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned discharge instructions template
Number of subjects: 225
Study 34345921 — intervention group
Group type: COMPARATOR
Intervention: Baseline readmission rate
Number of subjects: 225
Study 34345921 — intervention group
Group type: COMPARATOR
Intervention: After educational outreach
Number of subjects: 225
Study 34345921 — intervention group
Group type: COMPARATOR
Intervention: After redesigned template
Number of subjects: 225
Study 34345921 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 225
Study 34345921 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents
Number of subjects: 225
Study 32476465 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 32476465 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 34184620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 52
Study 34184620 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 52
Study 34184620 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 52
Study 35078832 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Antenatal Educational Program on Allergic Diseases (PAEPAD)
Number of subjects: 2266
Study 35078832 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal care education
Number of subjects: 2266
Study 33124789 — intervention group
Group type: EXPERIMENTAL
Intervention: Core training (30‐35 min, three days a week for eight weeks)
Number of subjects: 24
Study 33124789 — intervention group
Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 24
Study 35596945 — intervention group
Group type: EXPERIMENTAL
Intervention: Mbereko+Men intervention
Number of subjects: 457
Study 35596945 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 457
Study 33222542 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with Y-90 resin microspheres
Number of subjects: 0
Study 33222542 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 36494706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac shockwave therapy (SWT) during CABG surgery
Number of subjects: 80
Study 36494706 — intervention group
Group type: COMPARATOR
Intervention: CABG surgery with sham treatment
Number of subjects: 80
Study 32342235 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 72
Study 32342235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 35780574 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS (1, 2, and 3 mA)
Number of subjects: 11
Study 35780574 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 32964809 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-indicated treatment in STEPd study
Number of subjects: 351
Study 32964809 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-indicated treatment in FreqMech study
Number of subjects: 351
Study 32964809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-trial predictions for indicated treatment
Number of subjects: 351
Study 32557665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous garetosmab 0.3, 1, 3, or 10 mg/kg
Number of subjects: 40
Study 32557665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous garetosmab 10 mg/kg
Number of subjects: 40
Study 32557665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 36163755 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib (40 mg/day from days 8-21, followed by 30-60 mg/day for up to 3 years)
Number of subjects: 539
Study 36163755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 36163755 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 539
Study 34336162 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence image group using hybrid segmentation network (HSN) model for analyzing brain images.
Number of subjects: 73
Study 34336162 — intervention group
Group type: COMPARATOR
Intervention: Control group using original images for diagnosis and treatment.
Number of subjects: 73
Study 35818232 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen combined with SHR‐1210
Number of subjects: 60